Currently, combination therapy with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy for hormone receptor-positive (HR+) HER2-negative (HER2−) recurrent breast cancer is generally chosen as a treatment strategy that emphasizes quality of life without aiming for a cure. Here, ERBB2 is linked to breast carcinoma.